A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
The purpose of Phase 1 of this study is to evaluate the safety of the combination regimen,
bexarotene and ZD1839. Phase II will evaluate the median survival, time to disease
progression, and toxicity.